Home › Funds › Affinity Asset Advisors, LLC › CGEM
Affinity Asset Advisors, LLC position in CGEM
CULLINAN THERAPEUTICS INC · Health Care
Affinity Asset Advisors, LLC reported holding 875,760 shares of CGEM (CULLINAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$13.4M, representing 0.63% of its reported portfolio and ranking #39 among its reported holdings. Affinity Asset Advisors, LLC has disclosed CGEM holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Affinity Asset Advisors, LLC's CGEM position evolved
Affinity Asset Advisors, LLC first disclosed a stake in CGEM in Q4 2023 at 300,000 shares (US$3.1M). The position peaked in Q4 2025 at 1,932,106 shares, worth US$20.0M. Across 12 filings, Affinity Asset Advisors, LLC increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 875,760 shares valued at US$13.4M. Notable position changes include a 632% increase in Q4 2025 (shares rose 37% over the following quarter), a 60% trim in Q1 2026 (shares rose 28% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 300.00K | $3.06M | New |
| Q1 2024 | 258.59K | $4.41M | Reduce |
| Q2 2024 | 263.82K | $4.60M | Add |
| Q3 2024 | 263.82K | $4.42M | Hold |
| Q4 2024 | 263.82K | $3.21M | Hold |
| Q1 2025 | 263.82K | $2.00M | Hold |
| Q2 2025 | 263.82K | $1.99M | Hold |
| Q3 2025 | 263.82K | $1.56M | Hold |
| Q4 2025 | 1.93M | $20.00M | Add |
| Q1 2026 | 781.26K | $11.10M | Reduce |
| Q2 2026 | 875.76K | $15.95M | Add |
| Q3 2026 | 875.76K | $13.44M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CGEM and 13F data
CGEM (CULLINAN THERAPEUTICS INC) is a Health Care company. 33 other funds we track also report a position in CGEM — the largest reported positions include MPM BioImpact LLC (US$177.2M), Lynx1 Capital Management LP (US$163.2M), BVF INC/IL (US$104.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CGEM
- MPM BioImpact LLC 9.73M sh · $177.21M · Q2 2026
- Lynx1 Capital Management LP 8.96M sh · $163.23M · Q2 2026
- BVF INC/IL 5.75M sh · $104.72M · Q2 2026
- Kynam Capital Management, LP 3.11M sh · $56.71M · Q2 2026
- RTW INVESTMENTS, LP 2.36M sh · $43.05M · Q2 2026
- Siren, L.L.C. 1.79M sh · $27.53M · Q3 2026
- Venrock Adviser, LLC 1.38M sh · $25.13M · Q2 2026
- Blue Owl Capital Holdings LP 1.40M sh · $21.49M · Q3 2026
- BOOTHBAY FUND MANAGEMENT, LLC 1.08M sh · $19.71M · Q2 2026
- BOONE CAPITAL MANAGEMENT LLC 704.44K sh · $12.83M · Q2 2026
- Elmind Capital, LP 690.00K sh · $12.56M · Q2 2026
- TWIN FOCUS CAPITAL PARTNERS, LLC 595.49K sh · $9.14M · Q3 2026
More on Affinity Asset Advisors, LLC
FAQ
How long has Affinity Asset Advisors, LLC held CGEM?
Affinity Asset Advisors, LLC has disclosed CGEM holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is Affinity Asset Advisors, LLC's current position in CGEM?
As of Q3 2026, Affinity Asset Advisors, LLC holds 875.76K shares of CGEM (CULLINAN THERAPEUTICS INC), valued at $13.44M, representing 0.63% of its reported portfolio and ranking #39.
Has Affinity Asset Advisors, LLC been buying or selling CGEM?
In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC held unchanged its position in CGEM. The position peaked in Q4 2025 at 1.93M shares.
Which other funds hold CGEM?
Other major institutional holders of CGEM include MPM BioImpact LLC, Lynx1 Capital Management LP, BVF INC/IL, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.